Gormley Glenn 4
4 · Aktis Oncology, Inc. · Filed Apr 16, 2026
Research Summary
AI-generated summary of this filing
Aktis Oncology Director Glenn Gormley Receives 37,866-Share Option Award
What Happened
Glenn Gormley, a director of Aktis Oncology, was granted stock options covering 37,866 shares on April 15, 2026. The Form 4 reports the acquisition as an award/derivative at $0.00 per share (transaction code A); no cash price or immediate sale was reported.
Key Details
- Transaction date: 2026-04-15; Form 4 filed 2026-04-16 (timely filing).
- Transaction type: Grant of stock options (derivative securities), code A.
- Quantity and price: 37,866 option shares @ $0.00 (reported acquisition value $0).
- Vesting (Footnote F1): 1/3 vests on April 15, 2027, then 1/3 annually thereafter, subject to continuous service.
- Shares owned after transaction: Not specified in the provided filing excerpt.
- Filing status: Timely (filed the day after the transaction).
Context
This was a compensation grant of options, not an open-market purchase or sale. The options only translate into owned shares if and when they vest (and are exercised); they do not by themselves indicate an immediate market buy or sell. Grants like this are common for director compensation and are primarily a retention/incentive tool rather than a direct signal of trading intent.
Insider Transaction Report
- Award
Stock Option (Right to Buy)
[F1]2026-04-15+37,866→ 37,866 totalExercise: $18.09Exp: 2036-04-15→ Common Stock (37,866 underlying)
Footnotes (1)
- [F1]1/3 of the original number of shares subject to the option shall vest on April 15, 2027, and 1/3 of the original number of shares subject to the option shall vest in equal annual installments thereafter, subject to the Reporting Person's continuous service through each vesting date, inclusive.